Decreased Expression of MiR-184 Restrains the Growth and Invasion of Endometrial Carcinoma Cells Through CDC25A-dependent Notch Signaling Pathway
Overview
Affiliations
Endometrial carcinoma (EC) is one of the most common malignancies of female reproductive tract in developed countries. MicroRNA is frequently dysregulated in human cancers and acts a key regulator role in tumor cell growth and metastasis. The aims of this study were to investigate the roles of microRNA-184 (miR-184) in EC cells and to identify its potential molecular mechanism. Here, the data revealed that miR-184 was significantly downregulated in human EC tissue compared with normal endometrial tissue, and the level of miR-184 expression was associated with lymph node metastasis and prognosis in patients with EC. In vitro assays, overexpression of miR-184 could suppress the proliferation and invasion of HEC-1B and RL95-2 cells. Moreover, bioinformatics analysis showed that cell division cycle 25A (CDC25A) was a putative target gene of miR-184. Dual luciferase reporter assay confirmed that miR-184 significantly downregulated CDC25A expression via directly interaction with the putative binding site in the 3'-untranslated region (3'-UTR) of CDC25A mRNA. Interestingly, knockdown of CDC25A resulted in inhibition of HEC-1B and RL95-2 cells growth and invasion. Mechanistic investigation revealed that downregulation of the Notch receptors (NOTCH1, NOTCH2, NOTCH3 and NOTCH4) and target gene HES1 by miR-184 could be reversed by CDC25A overexpression. In summary, our data demonstrate that CDC25A is a target gene of miR-184 in EC cells, and decreased expression of miR-184 suppresses the growth and invasion of EC cells via CDC25A-dependent Notch signaling pathway, suggesting that miR-184 may be a promising target for a new therapeutic strategy against EC.
microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance.
Fattahi M, Rezaee D, Fakhari F, Najafi S, Aghaei-Zarch S, Beyranvand P Cell Death Discov. 2023; 9(1):423.
PMID: 38001121 PMC: 10673883. DOI: 10.1038/s41420-023-01718-1.
Tan G, Leong S, Jin Y, Kuick C, Chee J, Low S Cancers (Basel). 2023; 15(21).
PMID: 37958433 PMC: 10648581. DOI: 10.3390/cancers15215260.
Thakur L, Thakur S Front Endocrinol (Lausanne). 2023; 14:1166948.
PMID: 37152960 PMC: 10161733. DOI: 10.3389/fendo.2023.1166948.
Wu C, Wang M, Huang Q, Guo Y, Gong H, Hu C J Clin Lab Anal. 2021; 36(1):e24108.
PMID: 34788477 PMC: 8761437. DOI: 10.1002/jcla.24108.
Unveiling osteosarcoma responses to DAPT combined with cisplatin by using confocal Raman microscopy.
Li J, Li J, Wang H, Qin J, Zeng H, Wang K Biomed Opt Express. 2021; 12(9):5514-5528.
PMID: 34692198 PMC: 8515968. DOI: 10.1364/BOE.432933.